These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 667791)

  • 1. Effects of radiochemotherapy and splenectomy on cellular immunity in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma.
    Steele R; Han T
    Cancer; 1978 Jul; 42(1):133-9. PubMed ID: 667791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
    J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of splenectomy on the invitro lymphocyte response to phytohemagglutinin and pokeweed mitogen in Hodgkin's disease.
    Wagener DJ; Geestman E; Wessels HM
    Cancer; 1975 Jul; 36(1):194-8. PubMed ID: 1203846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of radiochemotherapy and splenectomy on lymphoid subclasses in patients with Hodgkin's lymphoma in complete remission].
    Leoni P; Montroni M; Montillo M; Salvi A; Centurioni R; Fanciulli E
    G Clin Med; 1981 Oct; 62(10):685-92. PubMed ID: 6977469
    [No Abstract]   [Full Text] [Related]  

  • 5. A micro-method for PHA-induced stimulation of human lymphocytes. II. communication: effect of splenectomy on the inhibitory activity of serum in patients with Hodgkin's disease.
    Pappas A; Pees H; Girmann G
    Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):1-10. PubMed ID: 868205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas.
    Schreiber DP; Jacobs C; Rosenberg SA; Cox RS; Hoppe RT
    Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):31-6. PubMed ID: 3838166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of splenectomy on cellular immunologic parameters in Hodgkin's disease.
    Wagener DJ; Geestman E; Borgonjen A; Haanen C
    Cancer; 1976 May; 37(5):2212-9. PubMed ID: 130968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro lymphocyte response to the phytomitogens in untreated and treated patients with Hodgkin's disease.
    Romagnani S; Amadori A; Biti G; Bellesi G; Ricci M
    Int Arch Allergy Appl Immunol; 1976; 51(3):378-89. PubMed ID: 1279027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immediate effects of splenectomy, radiotherapy and intensive chemotherapy on the immune status of patients with malignant lymphoma.
    Hancock BW; Bruce L; Ward AM; Richmond J
    Clin Oncol; 1977 Jun; 3(2):137-44. PubMed ID: 872467
    [No Abstract]   [Full Text] [Related]  

  • 10. Transfer factor in Hodgkin's disease.
    Ng RP; Moran CJ; Alexopoulos CG; Bellingham AJ
    Lancet; 1975 Nov; 2(7941):901-3. PubMed ID: 53376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proportions and absolute count of T- and B-lymphocytes in peripheral blood and their blastic transformation induced by mitogens in splenectomized and non-splenectomized patients with Hodgkin's disease].
    Pluzańska A
    Acta Haematol Pol; 1978; 9(1):37-44. PubMed ID: 307325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term influence of splenectomy on immune functions in patients with Hodgkin's disease.
    Björkholm M; Askergren J; Holm G; Mellstedt H
    Scand J Haematol; 1980 Jan; 24(1):87-94. PubMed ID: 6966069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte subpopulations in Hodgkin's disease and non-Hodgkin's lymphoma and the effects of radiotherapy.
    Balasem AN; Barker CR
    Clin Radiol; 1984 Sep; 35(5):353-7. PubMed ID: 6236011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of splenectomy upon immunologic reactivity of patients with Hodgkin's disease.
    Rogan-Grgas J; Milas L; Hauptmann E; Nola P; Kolarić K; Maricić Z; Malenica B
    Tumori; 1981 Dec; 67(6):539-47. PubMed ID: 6977906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splenic T and B lymphocytes and their mitogenic response in untreated Hodgkin's disease.
    Han T; Minowada J; Subramanian V; Barcos M; Kim U
    Cancer; 1980 Feb; 45(4):767-74. PubMed ID: 6965606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity in Hodgkin's disease: status after 5 years' remission.
    Hancock BW; Bruce L; Whitham MD; Dunsmore IR; Ward AM; Richmond J
    Br J Cancer; 1982 Oct; 46(4):593-600. PubMed ID: 7138765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease.
    Bobrove AM; Fuks Z; Strober S; Kaplan HS
    Cancer; 1975 Jul; 36(1):169-79. PubMed ID: 54208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evidence of normal lymphocyte function in some patients with Hodgkin's disease and negative delayed cutaneous hypersensitivity.
    Churchill WH; Rocklin RR; Moloney WC; David JR
    Natl Cancer Inst Monogr; 1973 May; 36():99-106. PubMed ID: 4583000
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.
    Swerdlow AJ; Douglas AJ; Vaughan Hudson G; Vaughan Hudson B; MacLennan KA
    Br J Cancer; 1993 Nov; 68(5):1006-11. PubMed ID: 8217588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.